Cadrenal Files S-1 for Resale of 428K Shares, Acquires VLX-1005 Asset

TL;DR

**Cadrenal's S-1 is a red flag, signaling potential dilution from selling stockholders and a reliance on new asset acquisitions to drive future value without immediate cash infusion from this specific filing.**

AI Summary

Cadrenal Therapeutics, Inc. (CVKD) filed an S-1 on December 23, 2025, primarily for the resale of up to 428,227 shares of common stock by Selling Stockholders. This includes 414,748 shares issuable upon exercise of Common Warrants purchased in a private placement on December 16, 2025, and 13,479 shares from Placement Agent Warrants issued to H.C. Wainwright & Co., LLC. The company will not receive any proceeds from these sales. On December 15, 2025, Cadrenal completed a Registered Direct Offering of 207,374 shares of Common Stock and a concurrent Private Placement of Common Warrants to purchase 414,748 shares. Additionally, on December 10, 2025, Cadrenal entered into an Asset Purchase Agreement with Veralox Therapeutics Inc. to acquire all rights to VLX-1005, a Phase 2 12-lipoxygenase inhibitor for heparin-induced thrombocytopenia (HIT). The company's stock closed at $7.535 per share on December 22, 2025, on the Nasdaq Capital Market. Cadrenal is focused on developing novel anticoagulation management products, including tecarfarin for kidney dysfunction/LVAD patients and frunexian, a Phase 2-ready IV Factor XIa inhibitor for acute hospital settings.

Why It Matters

This S-1 filing signals Cadrenal's strategic shift towards expanding its pipeline with the acquisition of VLX-1005, a potential first-in-class treatment for HIT, a life-threatening complication. While the company won't receive direct proceeds from the resale of 428,227 shares by selling stockholders, the underlying private placement and registered direct offering on December 15, 2025, likely provided capital for this acquisition and ongoing clinical development. For investors, this indicates a focus on high-risk patient populations and a competitive play in the anticoagulation market, potentially challenging existing treatments like warfarin with tecarfarin and addressing unmet needs with frunexian and VLX-1005. The dilution from the warrant exercises and the potential for further sales by selling stockholders could impact share price.

Risk Assessment

Risk Level: medium — The S-1 filing itself is for the resale of 428,227 shares by Selling Stockholders, meaning Cadrenal Therapeutics, Inc. will not receive any proceeds from these sales, which could lead to market overhang and potential downward pressure on the stock. The company is also an 'emerging growth company' and a 'smaller reporting company,' indicating a higher inherent risk profile due to less stringent disclosure requirements and potentially limited resources compared to larger, more established firms.

Analyst Insight

Investors should closely monitor the volume and price action of CVKD shares as the Selling Stockholders begin to offload their 428,227 shares, as this could create selling pressure. Evaluate the long-term potential of the newly acquired VLX-1005 asset and the existing pipeline (tecarfarin, frunexian) against the backdrop of potential dilution and the company's 'smaller reporting company' status, which implies higher risk.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• 428,227 — Shares of Common Stock (Aggregate shares offered for resale by Selling Stockholders, from which the company receives no proceeds.)
• 414,748 — Common Warrant Shares (Shares issuable upon exercise of Common Warrants from the Private Placement, part of the resale.)
• 13,479 — Placement Agent Warrant Shares (Shares issuable upon exercise of Placement Agent Warrants, part of the resale.)
• 207,374 — Shares of Common Stock (Shares sold in the Registered Direct Offering on December 15, 2025.)
• $7.535 — Closing Price per Share (Closing price of CVKD on Nasdaq Capital Market on December 22, 2025.)
• 5% — Patients with HIT (Up to 5% of patients exposed to heparin can develop HIT, which VLX-1005 targets.)

Key Players & Entities

• Cadrenal Therapeutics, Inc. (company) — Registrant and issuer of common stock
• Veralox Therapeutics Inc. (company) — Seller of VLX-1005 assets
• H.C. Wainwright & Co., LLC (company) — Placement Agent for the Private Placement
• Quang Pham (person) — Chairman and Chief Executive Officer of Cadrenal Therapeutics, Inc.
• Leslie Marlow, Esq. (person) — Legal counsel from Blank Rome LLP
• Patrick Egan, Esq. (person) — Legal counsel from Blank Rome LLP
• Melissa Palat Murawsky, Esq. (person) — Legal counsel from Blank Rome LLP
• $0.001 (dollar_amount) — Par value per share of common stock
• $7.535 (dollar_amount) — Closing price of Common Stock on Nasdaq Capital Market on December 22, 2025
• Securities and Exchange Commission (regulator) — Regulatory body for S-1 filing

FAQ

Risk Factors

• Dilution from Stock Issuances [medium — financial]: The S-1 filing reveals the potential resale of 428,227 shares, including shares from warrant exercises. This significant number of shares, if sold, could dilute existing shareholders' ownership percentages and potentially depress the stock price.
• Drug Development and Approval Risks [high — regulatory]: Cadrenal is developing novel anticoagulation products like tecarfarin and frunexian, and has acquired VLX-1005. The success of these products is contingent on successful clinical trials, regulatory approvals (e.g., FDA), and market acceptance, all of which carry substantial risks and uncertainties.
• Competition in Anticoagulation Market [medium — market]: The anticoagulation market is competitive, with established players and ongoing innovation. Cadrenal's products will face competition from existing therapies and potentially new entrants, impacting market share and pricing power.
• Dependence on Key Personnel and Third Parties [medium — operational]: The company's success relies on its management team and scientific advisors. Furthermore, reliance on third-party manufacturers and clinical research organizations for drug development and production introduces operational risks and potential delays.
• Need for Future Financing [high — financial]: Developing pharmaceutical products is capital-intensive. Cadrenal will likely require significant future funding through equity or debt offerings to advance its pipeline, which could lead to further dilution or increased financial leverage.

Industry Context

Cadrenal Therapeutics operates in the highly competitive anticoagulation and thrombosis management market. This sector is characterized by significant R&D investment, stringent regulatory hurdles, and the presence of established pharmaceutical giants. Key trends include the development of novel anticoagulants with improved safety profiles (e.g., reduced bleeding risk) and targeted therapies for specific patient populations or conditions like HIT.

Regulatory Implications

The company faces substantial regulatory risks associated with the development and approval of its drug candidates, including tecarfarin, frunexian, and VLX-1005. Successful navigation of the FDA's drug approval process, including rigorous clinical trials and manufacturing compliance, is critical. The S-1 filing itself is a regulatory requirement for the resale of shares, ensuring transparency for investors.

What Investors Should Do

1. Monitor clinical trial progress and regulatory updates for VLX-1005, tecarfarin, and frunexian.
2. Assess the impact of the registered direct offering and warrant exercises on share dilution.
3. Evaluate the company's cash burn rate and future financing needs.
4. Analyze the competitive landscape for each of Cadrenal's pipeline assets.

Key Dates

• 2025-12-23: S-1 Filing — Initiates the process for resale of shares by selling stockholders, providing liquidity for certain investors and potentially signaling future market activity.
• 2025-12-16: Private Placement of Common Warrants — Resulted in the issuance of warrants that are now part of the shares being registered for resale, indicating a recent financing or transaction.
• 2025-12-15: Registered Direct Offering and Concurrent Private Placement — Raised capital or facilitated share distribution, with a portion of the shares now subject to resale, impacting the company's share structure.
• 2025-12-10: Asset Purchase Agreement with Veralox Therapeutics Inc. — Acquisition of VLX-1005, a key strategic move to expand the company's pipeline in the anticoagulation space, particularly for HIT.
• 2025-12-22: Stock Closing Price — Provides a current market valuation reference point of $7.535 per share on the Nasdaq Capital Market.

Glossary

S-1 Filing

A registration statement filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer securities to the public. It contains detailed information about the company's business, financial condition, and the securities being offered. (This filing pertains to the resale of existing shares, not a primary offering by the company, meaning the company receives no proceeds.)

Common Warrants

A type of security that gives the holder the right, but not the obligation, to purchase a company's stock at a specified price (the exercise price) within a certain period. (Shares issuable upon exercise of these warrants are included in the 428,227 shares being registered for resale.)

Placement Agent Warrants

Warrants issued to the agents (like investment banks) who help facilitate a private placement or offering, typically as part of their compensation. (These warrants are also part of the shares being registered for resale, indicating compensation to H.C. Wainwright & Co., LLC.)

Registered Direct Offering

A type of securities offering where a company sells newly issued shares directly to a small number of institutional investors, and these shares are registered with the SEC for resale. (Cadrenal conducted such an offering, selling 207,374 shares.)

Heparin-Induced Thrombocytopenia (HIT)

A serious immune-mediated complication of heparin therapy characterized by a significant drop in platelet count and a paradoxical increase in thrombotic events. (VLX-1005, acquired by Cadrenal, is a Phase 2 12-lipoxygenase inhibitor targeting HIT, a condition affecting up to 5% of patients exposed to heparin.)

12-lipoxygenase inhibitor

A type of drug that blocks the activity of the enzyme 12-lipoxygenase, which is involved in the production of certain inflammatory mediators. (VLX-1005 is an inhibitor of this enzyme and is being developed for HIT.)

Factor XIa inhibitor

A drug that inhibits Factor XIa, a protein in the blood clotting cascade. Inhibiting Factor XIa is a strategy to reduce thrombosis risk, potentially with a lower bleeding risk compared to traditional anticoagulants. (Cadrenal is developing frunexian, a Phase 2-ready IV Factor XIa inhibitor.)

Year-Over-Year Comparison

This S-1 filing focuses on the resale of shares by existing stockholders, stemming from recent financing activities including a registered direct offering and private placement of warrants. Unlike a typical S-1 for a primary offering, the company itself will not receive proceeds from these sales. The filing also highlights the recent acquisition of VLX-1005, indicating a strategic expansion of the company's therapeutic focus into heparin-induced thrombocytopenia (HIT), alongside its existing pipeline of anticoagulation products.

Key Financial Figures

• $0.001 — 8,227 shares of common stock, par value $0.001 per share (the “Common Stock&rdqu
• $7.535 — Stock on the Nasdaq Capital Market was $7.535 per share. Investing in our Common Sto
• $1.235 billion — gross revenue is equal to or more than $1.235 billion; (iii) the date on which we have issued
• $1 billion — date on which we have issued more than $1 billion in nonconvertible debt during the previ
• $250 million — reporting company” until we have $250 million or more in public float (based on Commo

Filing Documents

• ea0270736-s1_cadrenal.htm (S-1) — 278KB
• ea027073601ex5-1_cadrenal.htm (EX-5.1) — 7KB
• ea027073601ex23-1_cadrenal.htm (EX-23.1) — 2KB
• ea027073601ex-fee_cadrenal.htm (EX-FILING FEES) — 13KB
• image_001.jpg (GRAPHIC) — 5KB
• ex5-1_001.jpg (GRAPHIC) — 2KB
• 0001213900-25-125526.txt ( ) — 431KB
• ea027073601ex-fee_cadrenal_htm.xml (XML) — 5KB

Risk Factors

Risk Factors 4 Description of the Registered Direct Offering and the Concurrent Private Placement 6

Use of Proceeds

Use of Proceeds 8 Dividend Policy 8 Determination of the Offering Price 8

Description of Capital Stock

Description of Capital Stock 10 Selling Stockholders 14 Plan of Distribution 17 Legal Matters 18 Experts 18 Where You Can Find More Information 18 Incorporation of Certain Information by Reference 19 i ABOUT THIS PROSPECTUS You should rely only on the information we have provided or incorporated by reference into this prospectus and any related free writing prospectus. We have not authorized anyone to provide you with information different from that contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus. You must not rely on any unauthorized information or representation. This prospectus is an offer to sell only the shares of Common Stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus or any related free writing prospectus is accurate only as of the date on the front of the document and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus or any sale of a security. This prospectus and the documents incorporated by reference into this prospectus include statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We believe that the data obtained from these industry publications and third-party research, surveys and stu

View Full Filing

View this S-1 filing on SEC EDGAR